1. Home
  2. GNPX vs GNLN Comparison

GNPX vs GNLN Comparison

Compare GNPX & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

BUY

Current Price

$1.84

Market Cap

2.2M

Sector

Health Care

ML Signal

BUY

Logo Greenlane Holdings Inc.

GNLN

Greenlane Holdings Inc.

HOLD

Current Price

$2.02

Market Cap

2.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
GNLN
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Durable Goods
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.1M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
GNPX
GNLN
Price
$1.84
$2.02
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 164.8K
23.1K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.57
EPS
N/A
★ N/A
Revenue
N/A
★ $13,275,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.42
$1.51
52 Week High
$9.99
$139.60

Technical Indicators

Market Signals
Indicator
GNPX
GNLN
Relative Strength Index (RSI) 23.85 38.79
Support Level $0.80 $1.97
Resistance Level $2.12 $2.14
Average True Range (ATR) 0.21 0.22
MACD -0.03 -0.08
Stochastic Oscillator 4.39 15.52

Price Performance

Historical Comparison
GNPX
GNLN

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). It serves specialty retailers, smoke shops, head shops, convenience stores, and consumers. Geographically, it operates in United States, Canada, and Europe. It derives majority revenue from the United States. Its two operating segments are: Wholesale and Distribution, which includes legacy e-commerce and drop-ship operations; and Digital Assets, which includes digital asset treasury activities including acquisition, staking and validator participation related to BERA.

Share on Social Networks: